

KATE COSTELLO RETIRES AS DIRECTOR & CHAIR OF THE BOARD

Joanne Moss assumes role of Non-Executive Chair of the Board

Adelaide, Australia, 30 September 2021: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the **Company**), a leader in medical technology automation using artificial intelligence, advises of the retirement of Catherine “Kate” Costello from the Board of Directors, effective today.

Kate joined the Board in August 2005 when the Company (at the time known as Labtech Systems Ltd) was preparing to list on the ASX. In August 2017, Kate became Chair of the Board. The retirement as a Director and Chair is part of the Company’s planned Board renewal process, as previously announced to the market on 1 February 2021.

LBT CEO and Managing Director, Brent Barnes said:

“Kate has been a fantastic leader for the Company, overseeing LBT through many great achievements that have laid the foundations for our next stage of growth. Kate remains a dedicated supporter of the Company and our technology and I would like to personally thank her for her hard work and vision and the guidance provided to me personally during my time as CEO.”

As announced on 1 July 2021, Ms Joanne Moss will assume the role of LBT Chair, effective immediately. Joanne’s appointment as Chair follows a handover between Joanne and Kate as part of the planned transition of the role of Chair.

LBT Chair, Joanne Moss said:

“I am pleased to assume the role of Chair today. The Company is poised for an exciting period of commercial growth ahead. I look forward to working with the Company and its broader stakeholders to drive the global adoption by labs of the APAS® Independence and expand the utility of the APAS® technology towards new applications. I echo the thanks from the entire Board for Kate’s deep contribution to our progress.”

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company’s second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT’s 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. Beckman Coulter have also been appointed as Marketing Agent in Europe to assist in facilitating sales. The APAS® instrument is based upon LBT’s intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

CONTACTS

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: jgranger@hawkesburypartners.com